- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01266317
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations
This is an open-label Phase I/II trial to assess the feasibility and safety of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration on the outcome of hospitalized patients with acute IPF exacerbations. The specific aims of this study are:
- To assess the feasibility and safety of combined PEX, rituximab, and conventional corticosteroid administrations for the treatment of hospitalized patients with acute IPF exacerbations by monitoring indices of respiratory (PaO2) and cardiovascular function during the treatment interval.
- To assess the efficacy of combined PEX, rituximab, and conventional corticosteroid administrations for the treatment of hospitalized patients with acute IPF exacerbations on patient survival in comparison to historical controls. Patient survival for this investigation will be defined using the composite outcome of 60 day survival and/or survival to lung transplantation.
Subjects between 18 and 80 years of age who have a confirmed diagnosis of IPF, and meet all the study requirements will be enrolled in this study. A total of 10 subjects of both genders and all ethnic backgrounds with acute IPF exacerbations hospitalized at University of Pittsburgh Medical Center will be enrolled in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, open-label Phase II, non-randomized clinical trial to assess the feasibility and safety of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration in patients with acute IPF exacerbations.
INCLUSION CRITERIA:
- A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society Consensus Criteria.
- Unexplained worsening or development of dyspnea or hypoxemia within 30 days leading to the current hospitalization.
- Radiographic imaging showing ground-glass abnormality and/or consolidation superimposed on a background of reticular or honeycomb pattern consistent with UIP.
- Intent on the part of the treating physician to use high dose steroid therapy as a therapeutic effort to treat a diagnosis of acute IPF exacerbation.
EXCLUSION CRITERIA
- Diagnosis of documented infection based upon clinical evaluation and microbial testing.
- Diagnosis of thromboembolic disease by clinical assessment.
- Diagnosis of an additional etiology for ALI/ARDS based upon clinical assessment to include sepsis, aspiration, trauma, inhalational injury, acute pancreatitis, drug toxicity, blood product transfusion reaction, or stem cell transplantation.
- Diagnosis of congestive heart failure that accounts for the hypoxemia.
- Presence of active hepatitis B infection.
- Coagulopathy defined as an INR > 1.8, PTT > 2 x control, and platelet count < 50K.
- Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus or uncontrolled hypertension (systolic BP > 160 mm Hg and diastolic BP > 100 mm Hg) which would contraindicated the use of corticosteroids.
- Hemodynamic instability defined as a vasopressor requirement which would contraindicate the use of plasmapheresis.
- History of reaction to blood products, murine-derived products, or prior exposures to human-murine chimeric antibodies,
- History of malignancy.
- Inability or unwillingness to accept a blood transfusion.
- Inability or unwillingness to complete post- treatment surveillance for 60 days.
- Diagnosis of major comorbidities expected to interfere with subjects study participation for 60 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society Consensus Criteria.
- Unexplained worsening or development of dyspnea or hypoxemia within 30 days leading to the current hospitalization.
- Radiographic imaging showing ground-glass abnormality and/or consolidation superimposed on a background of reticular or honeycomb pattern consistent with usual interstitial pneumonia.
- Intent on the part of the treating physician to use high dose steroid therapy as a therapeutic effort to treat a diagnosis of acute IPF exacerbation.
Exclusion Criteria:
- Diagnosis of documented infection based upon clinical evaluation and microbial testing.
- Diagnosis of thromboembolic disease by clinical assessment.
- Diagnosis of an additional etiology for Acute Lung Injury/Acute Respiratory Distress Syndrome based upon clinical assessment to include sepsis, aspiration, trauma, inhalational injury, acute pancreatitis, drug toxicity, blood product transfusion reaction, or stem cell transplantation.
- Diagnosis of congestive heart failure that accounts for the hypoxemia.
- Presence of active hepatitis B infection.
- Coagulopathy defined as an International Normalized Ratio > 1.8, Partial Thromboplastin Time > 2 x control, and platelet count < 50,000.
- Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus or uncontrolled hypertension (systolic BP > 160 mm Hg and diastolic BP > 100 mm Hg) which would contraindicated the use of corticosteroids.
- Hemodynamic instability defined as a vasopressor requirement which would contraindicate the use of plasmapheresis.
- History of reaction to blood products, murine-derived products, or prior exposures to human-murine chimeric antibodies,
- History of malignancy.
- Inability or unwillingness to accept a blood transfusion.
- Inability or unwillingness to complete post- treatment surveillance for 60 days.
- Diagnosis of major comorbidities expected to interfere with subjects study participation for 60 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined PEX, Rituximab and Steroids
Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator. Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5. Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13. |
Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Respiratory and/or Hemodynamic Deteriorations
Time Frame: 28 days
|
To assess the feasibility and safety of combined PEX, rituximab, and conventional corticosteroid administrations for the treatment of hospitalized patients with acute IPF exacerbations by monitoring indices of respiratory (PaO2) and cardiovascular function during the treatment interval.
Respiratory deterioration was defined by a compilations of respiratory deteriorations (deteriorating gas exchange) and hemodynamic deteriorations (defined as a need for medical intervention).
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Survived to 60 Days or to Transplantation
Time Frame: 60 days
|
The secondary outcome measures a composite outcome defined as survival to 60 days or survival to transplantation at any time post therapy.
|
60 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO10110151
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IPF
-
Shanghai Henlius BiotechNot yet recruiting
-
Guangzhou Henovcom Bioscience Co. Ltd.Completed
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
University of NottinghamCompleted
-
Agomab Spain S.L.Recruiting
-
University of Colorado, DenverMayo Clinic; University of Pennsylvania; University of California, Los Angeles; University of TexasRecruiting
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
University Hospital, MontpellierCompletedInterstitial Lung Diseases | Non Definite IPFFrance, Italy
-
AmMax Bio, Inc.Withdrawn
Clinical Trials on Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
-
Hannover Medical SchoolNot yet recruitingAcute Liver FailureSpain, Germany, Mexico, Italy, Portugal
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.TerminatedThrombotic Thrombocytopenic PurpuraUnited States
-
Anhui Provincial HospitalNot yet recruitingHigh Titers of Anti-HLA Antibody (MFI ≥5000)China
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Banc de Sang i Teixits; IrsiCaixaCompletedPost-COVID19 ConditionSpain
-
Icahn School of Medicine at Mount SinaiBeth Israel Medical CenterTerminatedThrombotic Thrombocytopenic PurpuraUnited States
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
National Medical Research Center for Rehabilitation...Pirogov Russian National Research Medical University; DNKOM LLC; The Orenburg...RecruitingCardiovascular Diseases | Nervous System Diseases | Urologic Diseases | Diabetes | Neuromuscular Diseases | Hypercholesterolemia | Gout | Hyperbilirubinemia | Hyper IgE Syndrome | Hyper-LDL-cholesterolemia | Hyper Beta Lipoproteinemia | Hyper Eosinophilic SyndromeRussian Federation
-
Wladimir SzpirtOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsUnknownRespiratory Failure | Renal Failure, AcuteDenmark
-
University of RostockUnknown